Estrella Immunopharma Inc
NASDAQ:ESLA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Estrella Immunopharma Inc
Other Current Liabilities
Estrella Immunopharma Inc
Other Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
E
|
Estrella Immunopharma Inc
NASDAQ:ESLA
|
Other Current Liabilities
$375.3k
|
CAGR 3-Years
-14%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
B
|
Baker Hughes Co
NASDAQ:BKR
|
Other Current Liabilities
$8.6B
|
CAGR 3-Years
12%
|
CAGR 5-Years
8%
|
CAGR 10-Years
66%
|
|
|
Schlumberger NV
NYSE:SLB
|
Other Current Liabilities
$5.7B
|
CAGR 3-Years
65%
|
CAGR 5-Years
37%
|
CAGR 10-Years
12%
|
|
|
Halliburton Co
NYSE:HAL
|
Other Current Liabilities
$1.1B
|
CAGR 3-Years
4%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-4%
|
|
|
Symbotic Inc
NASDAQ:SYM
|
Other Current Liabilities
$1.2B
|
CAGR 3-Years
47%
|
CAGR 5-Years
59%
|
CAGR 10-Years
N/A
|
|
|
R
|
Reddit Inc
NYSE:RDDT
|
Other Current Liabilities
$40.4m
|
CAGR 3-Years
45%
|
CAGR 5-Years
18%
|
CAGR 10-Years
N/A
|
|
Estrella Immunopharma Inc
Glance View
Estrella Immunopharma Inc is a US-based company operating in industry. The company is headquartered in Emeryville, California. The company went IPO on 2021-07-19. Estrella Immunopharma, Inc. is a preclinical-stage biopharmaceutical company. The firm is developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Its lead product candidate, EB103, utilizes Eureka's ARTEMIS technology to target CD19, a protein expressed on the surface of almost all B-cell leukemias and lymphomas. The firm is also developing EB104, which also utilizes Eureka's ARTEMIS technology to target not only CD19, but also CD22, a protein that, like CD19, is expressed on the surface of most B-cell malignancies. The firm is also collaborating with Imugene Limited and its product candidate, CF33-CD19t an oncolytic virus (CF33-CD19t), to research the use of EB103 in conjunction with CF33-CD19t to treat solid tumors.
See Also
What is Estrella Immunopharma Inc's Other Current Liabilities?
Other Current Liabilities
375.3k
USD
Based on the financial report for Dec 31, 2025, Estrella Immunopharma Inc's Other Current Liabilities amounts to 375.3k USD.
What is Estrella Immunopharma Inc's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 3Y
-14%
Over the last year, the Other Current Liabilities growth was 2 436%. The average annual Other Current Liabilities growth rates for Estrella Immunopharma Inc have been -14% over the past three years .
